Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G Lipocine Inc. Filed by: Ikarian Capital, LLC

May 15, 2026 5:05 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent Common Stock, par value $0.0001 per share ("Common Stock") of Lipocine Inc. (the "Issuer"), held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 8,025,115 shares of Common Stock outstanding as of April 6, 2026, as disclosed in the Issuer's Definitive Proxy Statement, filed with the U.S. Securities and Exchange Commission (the "SEC") on April 21, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent Common Stock of the Issuer held by the Fund, and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 8,025,115 shares of Common Stock outstanding as of April 6, 2026, as disclosed in the Issuer's Definitive Proxy Statement, filed with the SEC on April 21, 2026.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:05/15/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:05/15/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).

ATTACHMENTS / EXHIBITS

EX-99.1

Categories

SEC Filings